Fresenius Medical Care AG (FMS)
| Market Cap | 12.92B |
| Revenue (ttm) | 21.46B |
| Net Income (ttm) | 734.93M |
| Shares Out | 293.41M |
| EPS (ttm) | 2.50 |
| PE Ratio | 17.58 |
| Forward PE | 9.43 |
| Dividend | $0.63 (2.87%) |
| Ex-Dividend Date | May 17, 2024 |
| Volume | 247,190 |
| Open | 21.85 |
| Previous Close | 22.18 |
| Day's Range | 21.80 - 22.20 |
| 52-Week Range | 17.93 - 22.76 |
| Beta | 0.85 |
| Analysts | Hold |
| Price Target | 23.00 (+3.98%) |
| Earnings Date | Nov 5, 2024 |
About FMS
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized... [Read more]
Financial Performance
In 2023, Fresenius Medical Care AG's revenue was 19.45 billion, an increase of 0.29% compared to the previous year's 19.40 billion. Earnings were 499.00 million, a decrease of -25.90%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for FMS stock is "Hold." The 12-month stock price forecast is $23.0, which is an increase of 3.98% from the latest price.
News
Hard work paying off despite challenges from U.S. weather-related events: Fresenius Medical Care CEO
Helen Giza, the CEO of Fresenius Medical Care, discusses the German healthcare firm's third-quarter earnings.
Fresenius Medical Care AG (FMS) Q3 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer an...
Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024
Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional E...
Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024
A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments. Company-wid...
Fresenius Medical Care: Let's Look At The Upside
Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E, and poised for growth by 2025-2026E. Despite recent earnings declines, the company expects growth...
Fresenius Medical Care Grows Number of U.S. Patients Using Company's Home Hemodialysis Machines, Launches NxStage® Versi®HD with GuideMe Software
Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapy This growth has generated greater adop...
Fresenius Medical Care CEO says strategy is working as company delivers on transformation efforts
Fresenius Medical Care CEO Helen Giza comments on the firm's second-quarter earning results.
Fresenius Medical Care AG (FMS) Q2 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS) Q2 2024 Earnings Call July 30, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin...
Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024
Organic revenue growth of +2.3% supported by both segments Care Delivery and Care Enablement Operating income1 and operating income margin1 increase driven by Care Enablement Additional FME25 savings ...
US FTC probing DaVita, Fresenius Medical, Politico reports
The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita and Fresenius Medical Care over allegations that the companies have been illegally thwarting smaller competitors, P...
Fresenius Medical Care: Significant Upside Remains
Fresenius Medical Care has underperformed since 2017, declining over 50% in the market. Despite the decline, the company remains a market leader in dialysis services with a strong product line. The co...
Fresenius Medical Care takes next important step towards goal to reduce CO2 emissions in its operations
Fresenius Medical Care enters virtual power purchase agreements for renewable energy to clearly step forward in reducing CO2 emissions footprint Company enacts five virtual power purchase agreements f...
Moody's and S&P change Fresenius Medical Care's rating outlook to stable
The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating FME is expected to maintain its good growth mome...
Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024
Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence Company-wide experts highlight robust anonymized dialysis database CONVINCE study and the remarkable...
Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets
Today's Annual General Meeting was the first one following the change in legal form completed in November 2023 Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an incre...
Fresenius Medical sees up to 2% US dialysis growth by year-end
The number of kidney dialysis sessions provided by Fresenius Medical Care in its top market, the United States, could rise by as much as 2% by the end of the year, its CEO said, as the impact of the p...
Fresenius Medical Care AG (FMS) Q1 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Dominik Heger - Head, IR Helen Giza - CEO and Chair Martin Fischer - CFO Conference C...
We have positive momentum in operating performance: Fresenius Medical Care CEO
Helen Giza, CEO of Fresenius Medical Care, joins CNBC's Annette Weisbach to discuss the company's 2024 first-quarter earnings results.
Fresenius Medical Care starts the year with strong earnings growth
Solid revenue1 growth of 4% driven by both segments Care Delivery and Care Enablement Operating income1 margin improved in both segments Care Enablement delivered strong sequential margin improvemen...
Fresenius Medical beats earnings expectations, keeps outlook; shares sink
Fresenius Medical Care beat first-quarter operating earnings expectations on Tuesday amid higher pricing and cost-cut savings, but the German company still maintained its profit outlook for 2024, send...
Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care
Fresenius Medical Care delivers on commitments during a year of fundamental transformation Progress towards sustainability goals in key areas: patient satisfaction, diversity in management, climate ta...
Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device
For the first time, Fresenius Medical Care develops and utilizes "Augmented Reality" (AR) to train medical staff in Intensive Care Units (ICUs) The new training application for ICU staff combines digi...
Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources
Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board role Jörg Häring contributes his extensive expertise from the energy, industry, and he...
Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador
Divestment of assets includes four separate country transactions to DaVita Inc. for USD 300 million Transactions further reduce the Company`s clinic footprint in Latin America, following the exit from...
Fresenius Medical Care AG (FMS) Q4 2023 Earnings Call Transcript
Fresenius Medical Care AG (FMS) Q4 2023 Earnings Call Transcript